U.S. markets open in 7 hours 36 minutes

Sinopharm Group Co., Ltd. (1099.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
19.120-0.760 (-3.82%)
As of 2:39PM HKT. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close19.880
Open19.520
Bid19.120 x 0
Ask19.140 x 0
Day's Range19.100 - 19.780
52 Week Range14.700 - 27.650
Volume8,393,433
Avg. Volume10,673,690
Market Cap56.818B
Beta (5Y Monthly)0.78
PE Ratio (TTM)8.11
EPS (TTM)2.358
Earnings DateMar 29, 2021 - Apr 02, 2021
Forward Dividend & Yield0.65 (3.45%)
Ex-Dividend DateJun 15, 2020
1y Target Est42.49
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Exclusive: Sinopharm-led consortium plans $3.3 billion take-private of HK-listed China TCM - sources
      Reuters

      Exclusive: Sinopharm-led consortium plans $3.3 billion take-private of HK-listed China TCM - sources

      A consortium led by state-owned pharma giant Sinopharm plans to take private China Traditional Chinese Medicine Holdings in a deal that would value the firm at at least $3.3 billion, said two people with direct knowledge of the matter. Sinopharm, China TCM's parent and major shareholder, is teaming up with the next two biggest stockholders, Ping An Insurance Group Co of China and executive director Wang Xiaochun, said the people, with the three holding a combined 49.4% stake. It plans to offer at least HK$5.10 ($0.66) per share for China TCM, the people said, a premium of about 33% to the average share price over the past month of HK$3.83.

    • Reuters

      Peru volunteer in Sinopharm vaccine trial dies of COVID-19 pneumonia, university says

      A volunteer in the local Peruvian trial of Sinopharm Group Co Ltd's coronavirus vaccine has died from COVID-19 related pneumonia, the university carrying out the trial said on Tuesday. Cayetano Heredia University, which is involved with the study, said that it did not know if the volunteer had received the vaccine or the placebo in the double blind trial. Peru is being hit by a second wave of COVID-19 infections.

    • Peru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines
      Reuters

      Peru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines

      China's Sinopharm Group and Pfizer Inc have requested approval for use of their COVID-19 vaccines in Peru as the Andean country grapples with a second wave of the coronavirus, a health official said on Tuesday. Carmen Ponce, general director of state drug regulator Digemid, said both drugmakers requested the registration last week after presenting "preliminary information" from their Phase III COVID-19 vaccine trials. Ponce added that authorization requests from other vaccine makers, such as AstraZeneca Plc and Russia's Gamaleya, are expected in the next few days.